Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Equity Average (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Equity Average over the past 12 years, most recently at $612.6 million for Q4 2025.

  • Quarterly results put Equity Average at $612.6 million for Q4 2025, down 11.17% from a year ago — trailing twelve months through Dec 2025 was $612.6 million (down 11.17% YoY), and the annual figure for FY2025 was $696.9 million, up 25.16%.
  • Equity Average for Q4 2025 was $612.6 million at Viridian Therapeutics, Inc.\DE, up from $509.1 million in the prior quarter.
  • Over the last five years, Equity Average for VRDN hit a ceiling of $689.6 million in Q4 2024 and a floor of $102.5 million in Q2 2021.
  • Median Equity Average over the past 5 years was $367.8 million (2023), compared with a mean of $381.8 million.
  • Biggest five-year swings in Equity Average: soared 618.98% in 2021 and later decreased 17.68% in 2025.
  • Viridian Therapeutics, Inc.\DE's Equity Average stood at $196.2 million in 2021, then skyrocketed by 104.96% to $402.0 million in 2022, then fell by 9.76% to $362.8 million in 2023, then soared by 90.07% to $689.6 million in 2024, then decreased by 11.17% to $612.6 million in 2025.
  • The last three reported values for Equity Average were $612.6 million (Q4 2025), $509.1 million (Q3 2025), and $559.8 million (Q2 2025) per Business Quant data.